First-Line and Second-Line T Cell Lymphoma Treatments

T cell lymphoma treatment options for these cancers are not especially effective and there is no absolute consensus about optimal treatments for most subtypes of T cell lymphoma because T cell lymphomas are relatively rare, representing about 15% of all non-Hodgkin's lymphomas diagnosed annually. Many T cell lymphoma subtypes, perhaps a majority, have a relatively poor prognosis with or without T cell lymphoma treatment.

First-Line T Cell Lymphoma Treatment

First-line therapeutic intervention for cases of noncutaneous peripheral T cell lymphomas remains relatively poorly explored, but some chemotherapy regimens are advocated in widely published T cell lymphoma treatment guidelines, such as:

  • CHOP (cyclophosphamide, vincristine, doxorubucin and prednisone)
  • DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin)
  • HyperCVAD (doxorubicin, vincristine, cyclophosphamide and dexamethasone)
  • High dose chemotherapy followed by a stem cell transplantation

Some T cell lymphoma patients may be guided towards a clinical trial as first-line therapy, depending on the diagnosis, staging, and other factors.

Second-Line T Cell Lymphoma Treatment

Second-line therapies for T cell lymphoma treatment include the following combination chemotherapy regimens, provided the patient is a candidate for stem cell transplantation:

  • DHAP (dexamethasone, cisplatin and cytarabine)
  • ESHAP (etopiside, methylprednisolone, cytarabine and cisplatin)
  • GDP (gemcitabine, dexamethasone and cisplatin
  • ICE (ifosfamide, carboplatin, etoposide)
  • MINE (mesna, ifosfamide, mitoxantrone and etoposide
  • Pralatrexate
  • GemOx (gemcitabine and oxaliplatin)

Similar to first-line options, for some patients referral to a clinical trial may constitute second-line therapy.

If the patient is not a candidate for stem cell transplantation, possible second-line therapies include the following:

  • Alemtuzumab
  • Bortezomib
  • Denileukin diftitox
  • Gemcitabine
  • Pralatrexate
  • Radiation

T cell lymphoma treatment options for less common T cell lymphoma subtypes, such as Adult T cell Leukemia/Lymphoma, as well as for cutaneous T cell lymphomas, will differ from what is presented here.

Source: National Comprehensive Cancer Network, Practice Guidelines in Oncology v.1., Peripheral T-Cell Lymphomas
Photo: Pexels

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...